Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

The Density Code for the Development of a Vaccine?

Cheng W.

J Pharm Sci. 2016 Nov;105(11):3223-3232. doi: 10.1016/j.xphs.2016.07.020. Review.

PMID:
27649885
2.

Factors related to HPV vaccine uptake and 3-dose completion among women in a low vaccination region of the USA: an observational study.

Wilson AR, Hashibe M, Bodson J, Gren LH, Taylor BA, Greenwood J, Jackson BR, She R, Egger MJ, Kepka D.

BMC Womens Health. 2016 Jul 22;16:41. doi: 10.1186/s12905-016-0323-5.

3.

Involvement of Nucleophosmin (NPM1/B23) in Assembly of Infectious HPV16 Capsids.

Day PM, Thompson CD, Pang YY, Lowy DR, Schiller JT.

Papillomavirus Res. 2015 Dec;1:74-89.

4.

Shift in prevalence of HPV types in cervical cytology specimens in the era of HPV vaccination.

Fischer S, Bettstetter M, Becher A, Lessel M, Bank C, Krams M, Becker I, Hartmann A, Jagla W, Gaumann A.

Oncol Lett. 2016 Jul;12(1):601-610.

5.

Rational Design of Peptide Vaccines Against Multiple Types of Human Papillomavirus.

Dey S, De A, Nandy A.

Cancer Inform. 2016 Jun 1;15(Suppl 1):1-16. doi: 10.4137/CIN.S39071.

6.

Natural history of cervical intraepithelial neoplasia in pregnancy: postpartum histo-pathologic outcome and review of the literature.

Mailath-Pokorny M, Schwameis R, Grimm C, Reinthaller A, Polterauer S.

BMC Pregnancy Childbirth. 2016 Apr 7;16:74. doi: 10.1186/s12884-016-0861-8. Review.

7.

Multiscale Modeling in the Clinic: Drug Design and Development.

Clancy CE, An G, Cannon WR, Liu Y, May EE, Ortoleva P, Popel AS, Sluka JP, Su J, Vicini P, Zhou X, Eckmann DM.

Ann Biomed Eng. 2016 Sep;44(9):2591-610. doi: 10.1007/s10439-016-1563-0.

PMID:
26885640
8.

Self-assembling protein nanoparticles in the design of vaccines.

López-Sagaseta J, Malito E, Rappuoli R, Bottomley MJ.

Comput Struct Biotechnol J. 2015 Nov 26;14:58-68. doi: 10.1016/j.csbj.2015.11.001. Review.

9.

Perceptions of Nigerian Women about Human Papilloma Virus, Cervical Cancer, and HPV Vaccine.

Akanbi OA, Iyanda A, Osundare F, Opaleye OO.

Scientifica (Cairo). 2015;2015:285702. doi: 10.1155/2015/285702.

10.

Chitosan-Poly (I:C)-PADRE Based Nanoparticles as Delivery Vehicles for Synthetic Peptide Vaccines.

Correia-Pinto JF, Csaba N, Schiller JT, Alonso MJ.

Vaccines (Basel). 2015 Sep 11;3(3):730-50. doi: 10.3390/vaccines3030730.

11.
12.

Human Papillomavirus: Current and Future RNAi Therapeutic Strategies for Cervical Cancer.

Jung HS, Rajasekaran N, Ju W, Shin YK.

J Clin Med. 2015 May 21;4(5):1126-55. doi: 10.3390/jcm4051126. Review.

13.

Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine.

Nygård M, Saah A, Munk C, Tryggvadottir L, Enerly E, Hortlund M, Sigurdardottir LG, Vuocolo S, Kjaer SK, Dillner J.

Clin Vaccine Immunol. 2015 Aug;22(8):943-8. doi: 10.1128/CVI.00133-15.

14.

Human papillomavirus vaccine: a boon or curse.

Chawla S, Singh I, Jain R, Mehta B, Kumari S, Sahoo SS.

Hum Vaccin Immunother. 2014;10(12):3509-12. doi: 10.4161/21645515.2014.980689.

15.

Surveillance of human papilloma virus using reference laboratory data for the purpose of evaluating vaccine impact.

Wilson AR, Welch RJ, Hashibe M, Greenwood J, Jackson B, She RC.

Online J Public Health Inform. 2014 Dec 15;6(3):e194. doi: 10.5210/ojphi.v6i3.5593.

16.

Long-peptide therapeutic vaccination against CRPV-induced papillomas in HLA-A2.1 transgenic rabbits.

Hu J, Budgeon LR, Balogh KK, Peng X, Cladel NM, Christensen ND.

Trials Vaccinol. 2014;3:134-142.

17.

The E3 ubiquitin ligase UBE3A is an integral component of the molecular circadian clock through regulating the BMAL1 transcription factor.

Gossan NC, Zhang F, Guo B, Jin D, Yoshitane H, Yao A, Glossop N, Zhang YQ, Fukada Y, Meng QJ.

Nucleic Acids Res. 2014 May;42(9):5765-75. doi: 10.1093/nar/gku225.

18.

Distribution of Human Papillomavirus 52 and 58 Genotypes, and Their Expression of p16 and p53 in Cervical Neoplasia.

Kim TE, Kim HW, Lee KE.

Korean J Pathol. 2014 Feb;48(1):24-9. doi: 10.4132/KoreanJPathol.2014.48.1.24.

19.

Protective vaccination against papillomavirus-induced skin tumors under immunocompetent and immunosuppressive conditions: a preclinical study using a natural outbred animal model.

Vinzón SE, Braspenning-Wesch I, Müller M, Geissler EK, Nindl I, Gröne HJ, Schäfer K, Rösl F.

PLoS Pathog. 2014 Feb 20;10(2):e1003924. doi: 10.1371/journal.ppat.1003924.

20.

Supplemental Content

Support Center